Medical and Clinical Pharmacology, Toulouse, France.
Br J Clin Pharmacol. 2023 Aug;89(8):2636-2638. doi: 10.1111/bcp.15757. Epub 2023 May 8.
Rhabdomyolysis is a serious adverse drug reaction of statins. There are few studies comparing the risk of rhabdomyolysis between the different statins. Using the WHO pharmacovigilance database, VigiBase®, we compared the risk of rhabdomyolysis reporting of seven statins (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin, with cerivastatin excluded). All reports of rhabdomyolysis in VigiBase® in adults with statins until 31 December 2022 were included. Results are expressed as reporting odds ratio (ROR, 95% CI). Among 10 657 reports with rhabdomyolysis with statins, simvastatin was the highest risk statin in comparison with others: ROR = 2.20 (2.11-2.29). The risk was higher in men, older than 74 years and in cases of drug interactions.
横纹肌溶解症是他汀类药物的一种严重不良反应。很少有研究比较不同他汀类药物发生横纹肌溶解症的风险。本研究使用世界卫生组织药物警戒数据库（VigiBase®），比较了 7 种他汀类药物（阿托伐他汀、氟伐他汀、洛伐他汀、匹伐他汀、普伐他汀、瑞舒伐他汀和辛伐他汀，不包括西立伐他汀）发生横纹肌溶解症报告的风险。纳入截至 2022 年 12 月 31 日在 VigiBase®中接受他汀类药物治疗的成年人横纹肌溶解症的所有报告。结果表示为报告比值比（ROR，95%CI）。在 10 657 例横纹肌溶解症与他汀类药物相关的报告中，与其他他汀类药物相比，辛伐他汀是风险最高的他汀类药物：ROR=2.20（2.11-2.29）。男性、年龄大于 74 岁和存在药物相互作用的情况下，风险更高。
